{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:08:25Z","timestamp":1790064505436,"version":"4.0.1"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402471"],"award-info":[{"award-number":["82402471"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32171343"],"award-info":[{"award-number":["32171343"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32471461"],"award-info":[{"award-number":["32471461"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1205803"],"award-info":[{"award-number":["2022YFA1205803"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.mtbio.2026.103260","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:06:32Z","timestamp":1779145592000},"page":"103260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["CXCR4 antagonistic lipid nanoparticles loading siRNA combat refractory AML through AML1-ETO depletion and homoharringtonine sensitization"],"prefix":"10.1016","volume":"38","author":[{"given":"Xuelu","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runxia","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanmei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3591-3139","authenticated-orcid":false,"given":"Tao","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5548-1858","authenticated-orcid":false,"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7287-9048","authenticated-orcid":false,"given":"Haiyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mtbio.2026.103260_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000536152","article-title":"Pathophysiology of acute myeloid leukemia","volume":"147","author":"Wachter","year":"2024","journal-title":"Acta Haematol."},{"key":"10.1016\/j.mtbio.2026.103260_bib2","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tips.2024.03.005","article-title":"AML treatment: conventional chemotherapy and emerging novel agents","volume":"45","author":"Forsberg","year":"2024","journal-title":"Trends in pharmacological sciences"},{"key":"10.1016\/j.mtbio.2026.103260_bib3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.mtbio.2026.103260_bib4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.mtbio.2026.103260_bib5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103260_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116774","article-title":"Acute myeloid leukemia with t(8;21) translocation: molecular pathogenesis, potential therapeutics and future directions","volume":"233","author":"Han Yu","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mtbio.2026.103260_bib7","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/86515","article-title":"AML1-ETO downregulates the granulocytic differentiation factor C\/EBPalpha in t(8;21) myeloid leukemia","volume":"7","author":"Pabst","year":"2001","journal-title":"Nature medicine"},{"key":"10.1016\/j.mtbio.2026.103260_bib8","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2002-04-1288","article-title":"The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia","volume":"101","author":"Vangala","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103260_bib9","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1158\/0008-5472.CAN-05-2944","article-title":"Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1","volume":"66","author":"Choi","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103260_bib10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbrc.2020.04.143","article-title":"The Gata1(low) murine megakaryocyte-erythroid progenitor cells expand robustly and alter differentiation potential","volume":"528","author":"Shin","year":"2020","journal-title":"Biochemical and biophysical research communications"},{"key":"10.1016\/j.mtbio.2026.103260_bib11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-981-10-3233-2_11","article-title":"RUNX1-ETO leukemia","volume":"962","author":"Lin","year":"2017","journal-title":"Advances in experimental medicine and biology"},{"key":"10.1016\/j.mtbio.2026.103260_bib12","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1073\/pnas.1019625108","article-title":"C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice","volume":"108","author":"Wang","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.mtbio.2026.103260_bib13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.exphem.2020.10.005","article-title":"RUNX1\/ETO and mutant KIT both contribute to programming the transcriptional and chromatin landscape in t(8;21) acute myeloid leukemia","volume":"92","author":"Chin","year":"2020","journal-title":"Experimental hematology"},{"key":"10.1016\/j.mtbio.2026.103260_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/418244a","article-title":"RNA interference","volume":"418","author":"Hannon","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.mtbio.2026.103260_bib15","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nchembio839","article-title":"RNAi therapeutics: a potential new class of pharmaceutical drugs","volume":"2","author":"Bumcrot","year":"2006","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.mtbio.2026.103260_bib16","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1038\/leu.2014.130","article-title":"Silencing AML1-ETO gene expression leads to simultaneous activation of both pro-apoptotic and proliferation signaling","volume":"28","author":"Spirin","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.mtbio.2026.103260_bib17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/leu.2008.157","article-title":"Transient depletion of RUNX1\/RUNX1T1 by RNA interference delays tumour formation in vivo","volume":"23","author":"Martinez Soria","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.mtbio.2026.103260_bib18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41375-023-01854-8","article-title":"Nanoparticle-mediated targeting of the fusion gene RUNX1\/ETO in t(8;21)-positive acute myeloid leukaemia","volume":"37","author":"Issa","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.mtbio.2026.103260_bib19","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1038\/s41375-024-02326-3","article-title":"CXCR4 as a therapeutic target in acute myeloid leukemia","volume":"38","author":"Korbecki","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.mtbio.2026.103260_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.7150\/thno.5150","article-title":"Role of CXCR4 in the pathogenesis of acute myeloid leukemia","volume":"3","author":"Peled","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.mtbio.2026.103260_bib21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/onc.2015.139","article-title":"CXCL12\/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks","volume":"35","author":"Guo","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.mtbio.2026.103260_bib22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2018.03.024","article-title":"CXCR4-mediated signaling regulates autophagy and influences acute myeloid leukemia cell survival and drug resistance","volume":"425","author":"Hu","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.mtbio.2026.103260_bib23","article-title":"Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia","volume":"98","author":"Cao","year":"2019","journal-title":"Medicine"},{"key":"10.1016\/j.mtbio.2026.103260_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bjh.16456","article-title":"Dissecting the role of the CXCL12\/CXCR4 axis in acute myeloid leukaemia","volume":"189","author":"Ladikou","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.mtbio.2026.103260_bib25","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia","volume":"119","author":"Uy","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103260_bib26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fonc.2018.00369","article-title":"Initial report of a phase i study of ly2510924, idarubicin, and cytarabine in relapsed\/refractory acute myeloid leukemia","volume":"8","author":"Boddu","year":"2018","journal-title":"Frontiers in oncology"},{"key":"10.1016\/j.mtbio.2026.103260_bib27","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cncr.33338","article-title":"BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed\/refractory acute myelogenous leukemia: an open-label safety and efficacy phase 2a study","volume":"127","author":"Borthakur","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.mtbio.2026.103260_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202001890","article-title":"Synthetic CXCR4 antagonistic peptide assembling with nanoscaled micelles combat Acute myeloid leukemia","volume":"16","author":"Meng","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.mtbio.2026.103260_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106503","article-title":"Nanomicelles co-loading CXCR4 antagonist and doxorubicin combat the refractory acute myeloid leukemia","volume":"185","author":"Zhang","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.mtbio.2026.103260_bib30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood.2023020857","article-title":"Canonical BAF complex regulates the oncogenic program in human T-cell acute lymphoblastic leukemia","volume":"143","author":"Aoki","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103260_bib31","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.V77.9.2031.2031","article-title":"Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation","volume":"77","author":"Asou","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103260_bib32","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.leukres.2011.05.014","article-title":"Heat shock protein 90 inhibition results in altered downstream signaling of mutant KIT and exerts synergistic effects on Kasumi-1 cells when combining with histone deacetylase inhibitor","volume":"35","author":"Yu","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.mtbio.2026.103260_bib33","doi-asserted-by":"crossref","first-page":"20121","DOI":"10.18632\/oncotarget.4041","article-title":"A novel SAHA-Bendamustine hybrid induces apoptosis of leukemia cells","volume":"6","author":"Yu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.mtbio.2026.103260_bib34","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1038\/leu.2012.49","article-title":"Depletion of RUNX1\/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding","volume":"26","author":"Ptasinska","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.mtbio.2026.103260_bib35","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1091\/mbc.e02-11-0714","article-title":"Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4","volume":"14","author":"Venkatesan","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.mtbio.2026.103260_bib36","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bjh.16456","article-title":"Dissecting the role of the CXCL12\/CXCR4 axis in acute myeloid leukaemia","volume":"189","author":"Ladikou","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.mtbio.2026.103260_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/srep34957","article-title":"AML1\/ETO accelerates cell migration and impairs cell-to-cell adhesion and homing of hematopoietic stem\/progenitor cells","volume":"6","author":"Saia","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mtbio.2026.103260_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20236003","article-title":"The role of reactive oxygen species in acute myeloid leukaemia","volume":"20","author":"Sillar","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2026.103260_bib39","first-page":"5","article-title":"Reactive oxygen species and its role in pathogenesis and resistance to therapy in acute myeloid leukemia","volume":"7","author":"Khorashad","year":"2024","journal-title":"Cancer drug resistance (Alhambra, Calif.)"},{"key":"10.1016\/j.mtbio.2026.103260_bib40","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1038\/leu.2009.143","article-title":"A robust xenotransplantation model for acute myeloid leukemia","volume":"23","author":"Sanchez","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.mtbio.2026.103260_bib41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.2042-7158.2012.01567.x","article-title":"Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems","volume":"65","author":"Tacar","year":"2013","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.mtbio.2026.103260_bib42","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-7-2","article-title":"Homoharringtonine and omacetaxine for myeloid hematological malignancies","volume":"7","author":"L\u00fc","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mtbio.2026.103260_bib43","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01437-1","article-title":"Venetoclax combined with azacitidine and homoharringtonine in relapsed\/refractory AML: a multicenter, phase 2 trial","volume":"16","author":"Jin","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.mtbio.2026.103260_bib44","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1158\/1541-7786.MCR-13-0114","article-title":"Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML","volume":"11","author":"Sison","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.mtbio.2026.103260_bib45","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.18632\/oncotarget.27356","article-title":"Flow cytometric significance of cellular alkaline phosphatase activity in acute myeloid leukemia","volume":"10","author":"Rico","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.mtbio.2026.103260_bib46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.lrr.2013.12.001","article-title":"Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia","volume":"3","author":"Delaunay","year":"2014","journal-title":"Leukemia research reports"},{"key":"10.1016\/j.mtbio.2026.103260_bib47","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48687-z","article-title":"The FLT3-ITD mutation and the expression of its downstream signaling intermediates STAT5 and Pim-1 are positively correlated with CXCR4 expression in patients with acute myeloid leukemia","volume":"9","author":"Cao","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mtbio.2026.103260_bib48","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13076","article-title":"Role of CXCR4 in the progression and therapy of acute leukaemia","volume":"54","author":"Su","year":"2021","journal-title":"Cell Prolif."},{"key":"10.1016\/j.mtbio.2026.103260_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106983","article-title":"The magnitude of CXCR4 signaling regulates resistance to quizartinib in FLT3\/ITD(+) cells via RUNX1","volume":"124","author":"Fukuda","year":"2023","journal-title":"Leuk. Res."},{"key":"10.1016\/j.mtbio.2026.103260_bib50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3324\/haematol.2020.262121","article-title":"Differentiation therapy of myeloid leukemia: four decades of development","volume":"106","author":"Madan","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.mtbio.2026.103260_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115709","article-title":"Advances in acute myeloid leukemia differentiation therapy: a critical review","volume":"215","author":"Abdel-Aziz","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.mtbio.2026.103260_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrc.2017.103","article-title":"Differentiation therapy revisited","volume":"18","author":"de Th\u00e9","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.mtbio.2026.103260_bib53","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1182\/blood-2002-05-1589","article-title":"AML1\/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells","volume":"101","author":"Heidenreich","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.mtbio.2026.103260_bib54","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf3735","article-title":"Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia","volume":"8","author":"Lam","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.mtbio.2026.103260_bib55","article-title":"Homoharringtonine: mechanisms, clinical applications and research progress","volume":"15","author":"Wang","year":"2025","journal-title":"Frontiers in oncology"}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426005041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006426005041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:45:53Z","timestamp":1790063153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006426005041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":55,"alternative-id":["S2590006426005041"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103260","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCR4 antagonistic lipid nanoparticles loading siRNA combat refractory AML through AML1-ETO depletion and homoharringtonine sensitization","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2026.103260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103260"}}